Weave
San Francisco
About Weave
Weave Bio is an AI-native, cloud-based, software company redesigning regulatory workflows and transforming how novel therapies navigate the complex path from lab to market. The Weave Platform is an end-to-end solution that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed. The Weave Platform has been widely adopted for preclinical IND preparation and earned industry recognition as the "Biotech AI Innovation of the Year" award winner. Weave Bio has since expanded platform capabilities across the platform to encompass clinical and approval-stage submissions, delivering a comprehensive AI workbench that accelerates regulatory timelines by more than 50% while improving review quality and ensuring compliance with FDA, EMA, and global regulatory standards. Founded in 2022 and headquartered in San Francisco, Weave bridges life sciences, regulatory expertise, AI innovation, and enterprise software to solve critical bottlenecks in drug development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $43.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2025)
- Website: weave.bio
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/weave-99474 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.